Qubit Pharmaceuticals Competitors and Similar CompaniesClear all
Qubit Pharmaceuticals's competitors and similar companies include Odyssey Therapeutics, Evaxion Biotech, ImmunoGen and Olema Oncology.
 Qubit Pharmaceuticals Qubit Pharmaceuticals is a company that provides physics-driven drug discovery solutions. |  Odyssey Therapeutics Odyssey Therapeutics is a company that develops precision immunomodulators and oncology medicines. |  Evaxion Biotech Evaxion Biotech A/S is a company focused on the development of vaccines against cancer and infectious diseases. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  Olema Oncology Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. | |
Founding Date | Founding Date 2020 | Founding Date 2021 | Founding Date 2008 | Founding Date 1981 | Founding Date 2007 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Paris, FR HQ | Locations Boston, US HQ Frankfurt Am Main, DE Ann Arbor, US San Diego, US | Locations København, DK HQ | Locations Waltham, US HQ | Locations San Francisco, US HQ San Francisco, US |
Employees | Employees 701% decrease | Employees 1481% decrease | Employees 558% decrease | Employees 277161% increase | Employees 9630% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 16.2 m | Valuation ($) 8.7 b | Valuation ($) 679.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €76.7k (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $7.5m (FY, 2025) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $176k (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $7.5m (FY, 2025) | Gross profit $108.6m (FY, 2022) | Gross profit N/A |
Net income | Net income (€133.4k) (FY, 2023) | Net income N/A | Net income ($7.7m) (FY, 2025) | Net income ($222.9m) (FY, 2022) | Net income ($162.5m) (FY, 2025) |
Operating ⚠ | |||||
Patent Applications | Patent Applications N/A | Patent Applications N/A | Patent Applications 34 (Feb, 2021) | Patent Applications 600 (FY, 2020) | Patent Applications N/A |
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued 12 (Feb, 2021) | Patents Issued 1.4 k (FY, 2020) | Patents Issued N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 386m | Total funding raised $ 17m | Total funding raised $ 56m | Total funding raised $ 145.1m |
For sources of this data, please see the company profile
View Company Profiles
Odyssey Therapeutics
HQ
Boston, US
Employees
148↓ 1% decrease
Odyssey Therapeutics is a company that develops precision immunomodulators and oncology medicines.
View companyEvaxion Biotech
HQ
København, DK
Employees
55↓ 8% decrease
Evaxion Biotech A/S is a company focused on the development of vaccines against cancer and infectious diseases.
View companyImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyOlema Oncology
HQ
San Francisco, US
Employees
96↑ 30% increase
Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers.
View company